https://www.selleckchem.com/pr....oducts/anlotinib-al3
40%. Median disease-free survival after resection was 10.9 months in arm 1 and 14.2 months in arm 2. This phase 2 randomized clinical trial did not demonstrate an improved OS with perioperative chemotherapy, compared with historical data from adjuvant trials in resectable pancreatic cancer. Two-year OS was 47% with mFOLFIRINOX and 48% with gemcitabine/nab-paclitaxel for all eligible patients starting treatment for resectable PDA. The trial also demonstrated adequate safety and high resectability rates with perioperative chemoth
Like
Comment
Share
